Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

/p>

3 months to September 9 months to September 30, 30, 2011 2010 2011 2010 $M $M $M $M Net cash provided by operating activities 178.7 142.0 664.2 612.0 Capital expenditure (1) (40.9) (53.5) (135.9) (139.7) Non GAAP free cash flow 137.8 88.5 528.3 472.3

(1) Capital expenditure for the nine months ended September 30, 2010 excludes capital expenditure relating to the acquisition of Lexington Technology Park.

Non GAAP net debt comprises:

September 30, December 31, 2011 2010 $M $M Cash and cash equivalents 276.4 550.6 Restricted cash 21.0 26.8 Convertible bonds (1,100.0) (1,100.0) Building finance obligation (8.3) (8.4) Non GAAP net debt (810.9) (531.0)

NOTES TO EDITORS

THE "SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicines products, as well as the ability to secure new products for commercialization and/or development; government regulation of Shire's products; Shire's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on Shire's products; Shire's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; Shire's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Calif. , May 16, 2013 Scientists ... Beijing , and the ... ) have demonstrated a novel therapy for reversing memory ... magnesium levels, they find significant cognitive improvement in advanced ... demonstrate a mechanism for reversing cognitive decline for advanced ...
(Date:5/16/2013)... Canada (PRWEB) May 16, 2013 On ... and costs over one billion dollars. Despite this investment, ... With stakes this high, is your clinical trial design ... deliver the best outcomes? , Dr. Frederic Sax, Global ... will discuss the use of data, information and technology ...
(Date:5/16/2013)... , May 16, 2013 ... research report is available in its ... Cardiac Biomarkers for Acute Coronary Syndromes ... http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Acute Coronary Syndromes - APAC Analysis ...
(Date:5/16/2013)... DNA Genotek, a leading provider of products for ... program in conjunction with the African Society of Human Genetics ... reduce the cost of DNA collection for locally ... and Health in Africa (H3 Africa) Initiative and to facilitate ... the AfSHG is to build the capacity of ...
Breaking Biology Technology:Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8DNA Genotek Inc. Announces Spit for Africa Program 2DNA Genotek Inc. Announces Spit for Africa Program 3
... , ... leading biopharma executives will discuss how Earned Value Management can improve control over clinical ... Annual Meeting in San Diego. , ... Chicago, IL (PRWEB) June 11, 2009 -- ClearTrial ( www.cleartrial.com ), ...
... 11 Medivation, Inc. (Nasdaq: MDVN ) ... patient enrollment in the CONNECTION study, a six-month, confirmatory, ... in patients with mild-to-moderate Alzheimer,s disease. , ... enrolled 598 patients, exceeding the enrollment target of 525 ...
... BioStorage Technologies, Inc., a worldwide provider of long- ... cold chain logistics, announced it will participate in ... Biorepositories Conference, September 21 to 23, 2009 in ... , Biorepositories 2009 is the only U.S.-based biobanking ...
Cached Biology Technology:ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 3Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 4BioStorage Technologies Takes Lead Sponsorship Role of 2nd Annual IIR Biorepositories Conference 2BioStorage Technologies Takes Lead Sponsorship Role of 2nd Annual IIR Biorepositories Conference 3
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Society for Developmental Biology (SDB) 72nd Annual ... These awards are meant to promote the entry ... into the mainstream of the basic science community ... at the SDB 2013 Annual Meeting. , Awards ...
(Date:5/16/2013)... MIT may someday eliminate the need for patients ... blood-sugar levels and inject themselves with insulin. , ... in the body and respond by secreting the ... of pancreatic islet cells, which are destroyed in ... of system could ensure that blood-sugar levels remain ...
(Date:5/16/2013)... SPARTANBURG, S.C. , May 16, 2013 /PRNewswire/ ... film in combination with a custom thin film ...  the highest forensic quality roll image in the ... market today. Sherlock, an Appendix F Mobile ID ... provides a 95% reduction in size and weight ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... indicates an increased risk for developing breast cancer can ... according to a new study featuring work from researchers ... and their colleagues. The multidisciplinary team found that ... more likely to be present in breast cancer patients ...
... AMES, Iowa Wind turbines in Midwestern farm fields ... turbine blades that generate renewable energy might also help corn ... off fungal infestations and improve their ability to extract growth-enhancing ... at the annual meeting of the American Geophysical Union, a ...
... nothing more powerful in a physician,s arsenal than early detection. ... remains a common and significant health problem in the United ... breast cancer in their lifetime and more than half of ... cure or effective therapeutic available. Using a new, powerful ...
Cached Biology News:Key information about breast cancer risk and development is found in 'junk' DNA 2Key information about breast cancer risk and development is found in 'junk' DNA 3Wind turbines may benefit crops 2Wind turbines may benefit crops 3Scientists discover powerful biomarker panel for the early detection of breast cancer 2Scientists discover powerful biomarker panel for the early detection of breast cancer 3
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... First-Strand cDNA Labeling System - dCTP ... reactions. For the generation and purification ... are packaged together for complete cDNA ... can be used for performing labeling ...
... Cy5 Post-Labeling Reactive Dye Pack, 12 ... fluors specifically optimized for microarray labeling.Higher ... pmol reactive dye per vial, at ... use, individually dispensed, and packed in ...
Biology Products: